Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 11 pages · English
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim data from additional cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026 Cash and cash equivalents of approximately $34.52 million provide runway
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- RAD101 interim Phase 2b data - 92% achieve primary endpoint
Later from Radiopharm Theranostics
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
- Half Year Report and Appendix 4D 31 December 2025
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics